Results 321 to 330 of about 616,799 (361)

Immunity

Emerging Infectious Diseases, 2016
openaire   +2 more sources

A study on the willingness and influencing factors of non-EPI vaccines recommendations among Chinese vaccination staff under major infectious disease outbreaks. [PDF]

Hum Vaccin Immunother
Qixin X, Liu Y, Che X, Du J, Xu Y, Han J, Lu Z, Yang Y, Gu W.   +8 more
europepmc   +1 more source

Chimeric receptor-binding domain vaccine design and sequential immunization enhanced broadly neutralizing antibody responses against COVID-19. [PDF]

Front Immunol
Yang X, Tang X, Sun Y, Xi H, Peng W, Yan L, Teng W, Zang Y, Jiang C.   +8 more
europepmc   +1 more source

Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvant. [PDF]

Immunohorizons
Larsen SE, Rais M, Reese VA, Ferede D, Pecor T, Kaur S, Nag D, Smytheman T, Gray SA, Carter D, Baldwin SL, Coler RN.   +11 more
europepmc   +1 more source

Respiratory syncytial virus immunization with nirsevimab: Acceptance and satisfaction assessment in infants and risk groups in the region of Murcia (Spain). [PDF]

Hum Vaccin Immunother
Jesús Pérez Martín J, de la Cruz Gómez Moreno M, Sánchez Manresa S, Del Pilar Ros Abellán M, Zornoza-Moreno M.   +4 more
europepmc   +1 more source

Monosaccharide-Based Synthetic TLR4 Agonist Enhances Vaccine Efficacy against <i>Pseudomonas aeruginosa</i> Challenge. [PDF]

ACS Infect Dis
Sainz-Mejías M, Ma C, Hou Y, Jurado-Martin I, Romerio A, Franco AR, Shaik MM, Tomás-Cortázar J, Peri F, McClean S.   +9 more
europepmc   +1 more source

Vaccinome Landscape in Nearly 620 000 Patients With Diabetes.

J Clin Endocrinol Metab
D'Addio F, Lazzaroni E, Lunati ME, Preziosi G, Ercolanoni M, Turola G, Marrocu C, Cicconi G, Sharma S, Scarioni S, Montefusco L, Pastore I, Morpurgo PS, Rossi A, Gandolfi A, Tinari C, Rossi G, Ben Nasr M, Loretelli C, Fiorina RM, Grassa B, Terranova R, Bucciarelli L, Berra C, Cereda D, Zuccotti G, Borriello CR, Fiorina P.   +27 more
europepmc   +1 more source